# Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

> **NCT06827145** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Center, China** · enrollment: 30 (estimated)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Vebreltinib
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT06827145
- **Lead sponsor:** National Cancer Center, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-14
- **Primary completion:** 2026-09
- **Final completion:** 2028-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06827145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06827145, "Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06827145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*